The Impact of Treatment Choice for Localized Prostate Cancer on Response to Phosphodiesterase Inhibitors
View All Author InformationAbstract
Purpose:
We determined whether the impact of phosphodiesterase inhibitors on sexual function and sexual bother is different after radical prostatectomy vs radiation therapy for localized prostate cancer.
Materials and Methods:
We analyzed data from 1,087 men treated for localized prostate cancer with radical prostatectomy or radiation therapy, who had at least 2 years of health related quality of life followup and who reported using a phosphodiesterase type 5 inhibitor after prostate cancer treatment. Sexual function and bother were assessed over time using the UCLA Prostate Cancer Index. Mixed model analysis was used to examine sexual function and sexual bother over time after initiation of treatment with a phosphodiesterase type 5 inhibitor. Response rates were then determined using the criterion of an increase in score of at least half the standard deviation in baseline scores, and multivariate logistic regression was used to identify predictors of improved sexual function and sexual bother in response to phosphodiesterase type 5 inhibitor use.
Results:
Patients treated with radical prostatectomy and those who received radiation therapy had an improvement in sexual function and sexual bother after initiating phosphodiesterase type 5 inhibitor use. Response rates were similar for both types of treatment, and the only significant predictors of response to phosphodiesterase type 5 inhibitors were higher baseline (pretreatment) sexual function score and lower sexual function before phosphodiesterase type 5 inhibitor use. There was no significant change in response to phosphodiesterase type 5 inhibitors over time.
Conclusions:
Analysis of these data suggests that choice of treatment for localized prostate cancer is unlikely to have a significant impact on response to phosphodiesterase type 5 inhibitors should they be needed after treatment. However, patients with better pretreatment sexual function are more likely to respond to phosphodiesterase type 5 inhibitors.
References
- 1 : Sexual function and bother after radical prostatectomy or radiation for prostate cancer: multivariate quality-of-life analysis from CaPSURE: Cancer of the Prostate Strategic Urologic Research Endeavor. Urology1999; 54: 503. Google Scholar
- 2 : Long-term outcomes among localized prostate cancer survivors: health-related quality-of-life changes after radical prostatectomy, external radiation, and brachytherapy. J Clin Oncol2005; 23: 2772. Google Scholar
- 3 : 5-year urinary and sexual outcomes after radical prostatectomy: results from the prostate cancer outcomes study. J Urol2005; 173: 1701. Link, Google Scholar
- 4 : Time course and predictors of symptoms after primary prostate cancer therapy. J Clin Oncol2003; 21: 3979. Google Scholar
- 5 : Elucidating the etiology of erectile dysfunction after definitive therapy for prostatic cancer. Int J Radiat Oncol Biol Phys1998; 40: 129. Crossref, Medline, Google Scholar
- 6 : Oral sildenafil in the treatment of erectile dysfunction: Sildenafil Study Group. N Engl J Med1998; 338: 1397. Google Scholar
- 7 : Treatment of erectile dysfunction with sildenafil citrate (Viagra) after radiation therapy for prostate cancer. Urology1999; 54: 308. Google Scholar
- 8 : The efficacy of sildenafil citrate following radiation therapy for prostate cancer: temporal considerations. J Urol2005; 174: 258. Link, Google Scholar
- 9 : Long-term potency after iodine-125 radiotherapy for prostate cancer and role of sildenafil citrate. Urology2003; 62: 1103. Google Scholar
- 10 : Long-term effect of sildenafil citrate on erectile dysfunction after radical prostatectomy: 3-year follow-up. Urology2003; 62: 110. Google Scholar
- 11 : Sildenafil citrate effectively reverses sexual dysfunction induced by three-dimensional conformal radiation therapy. Urology2001; 57: 769. Google Scholar
- 12 : Prospective pilot study of sildenafil for treatment of postradiotherapy erectile dysfunction in patients with prostate cancer. J Clin Oncol1999; 17: 3444. Google Scholar
- 13 : Efficacy of oral sildenafil in patients with erectile dysfunction after radiotherapy for carcinoma of the prostate. Urology1999; 53: 775. Google Scholar
- 14 : Role of Viagra after radical prostatectomy. Urology2000; 55: 241. Google Scholar
- 15 : The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure. Med Care1998; 36: 1002. Crossref, Medline, Google Scholar
- 16 : Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care2003; 41: 582. Google Scholar
- 17 : Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA1998; 280: 969. Crossref, Medline, Google Scholar
